Literature DB >> 12088761

Effect of experimental hypoalbuminemia on the plasma protein binding of tolmetin.

José Pérez-Urizar1, Francisco J Flores-Murrieta, Gilberto Castañeda-Hernández.   

Abstract

The purpose of this work was to study tolmetin plasma protein binding in an experimental model of hypoalbuminemia in the rat. Hypoalbuminemia was produced by repetitive plasmapheresis, achieving a 26.2 +/- 4.6% reduction in albumin circulating levels. Rats then received a 100 mg/kg oral tolmetin dose. Control rats received oral tolmetin 10, 56 or 100 mg/kg. Tolmetin plasma protein binding was determined by an ultrafiltration technique using an in vivo pharmacokinetic approach. Plasma protein binding data for the 3 doses studies in control animals could be described considering a single binding site with Kd = 21.9 +/- 2.1 microM and N = 0.98 +/- 0.05 sites per molecule of albumin. For hypoalbuminemic rats Kd was significantly increased (p < 0.05), while there was no significant change in the number of binding site per albumin molecule (Kd = 131.6 +/- 38.1 microM and N = 1.58 +/- 0.77). Our results show that hypoalbuminemia produces a disproportionate increase in the free fraction of tolmetin, not only by reducing albumin concentration, but also by a decrease in affinity. The mechanism responsible of such changes in affinity remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088761     DOI: 10.1016/s0024-3205(02)01788-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Interactions Between Sirolimus and Anti-Inflammatory Drugs: Competitive Binding for Human Serum Albumin.

Authors:  Arash Khodaei; Soheila Bolandnazar; Hadi Valizadeh; Leila Hasani; Parvin Zakeri-Milani
Journal:  Adv Pharm Bull       Date:  2016-06-30

2.  A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients.

Authors:  Huybrecht T'jollyn; An Vermeulen; Jan Van Bocxlaer; Pieter Colin
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.